

[Print this Page for Your Records](#) [Close Window](#)

**Control/Tracking Number:** 2024-A-3580-Diabetes

**Activity:** Abstract

**Current Date/Time:** 1/7/2024 12:14:34 PM

# **Sucralose consumption decreases insulin sensitivity and modifies the gut microbiota in healthy individuals**

**Author Block:** ALONSO ROMO-ROMO, MONICA SANCHEZ-TAPIA, NIMBE TORRES, CARLOS A. AGUILAR-SALINAS, ALEXANDRO J. MARTAGON, MARÍA GUADALUPE LÓPEZ-CARRASCO, LUZ E. GUILLÉN-PINEDA, PAOLA GOMEZ-AVILES, GRISELDA X. BRITO, FRANCISCO J. GÓMEZ-PEREZ, **PALOMA ALMEDA-VADES**, CDMX, Mexico, Ciudad de Mexico, Mexico, Mexico City, Mexico, Mexico, Mexico

## **Abstract:**

**Introduction:** Sucralose is a non-nutritive sweetener that has shown to decrease insulin sensitivity through mechanisms including changes in intestinal microbiota.

**Objective:** To determine the impact of sucralose on insulin sensitivity and gut microbiota in healthy individuals.


**Methods:** Parallel triple-blind randomized clinical trial including 24 healthy individuals, not habitual users of nonnutritive sweeteners. Individuals were instructed to maintain dietary and physical activity habits and randomized to consume capsules with 30% of the acceptable daily intake of sucralose or placebo for 30 days.

Hyperinsulinemic euglycemic clamp was performed before and after the intervention, M/I value change was calculated and compared. Stool samples were taken at baseline and the final visit, DNA extraction was carried out with a QIAamp DNA stool Mini Kit.

**Results:** The M/I value adjusted for free fat mass decreased in the sucralose group vs placebo ( $p<0.01$ ). Reduction in the alpha diversity of gut microbiota ( $p<0.0002$ ) was observed in sucralose consuming group vs placebo ( $p=0.2369$ ) and an increase in the Gram (-) bacteria *Bacteroides fragilis* associated to a significant increase in serum LPS were documented.

**Conclusion:** Sucralose consumption causes a significant decrease in insulin sensitivity associated to changes in gut microbiota composition and endotoxemia in healthy individuals.

Figure 1. A) Changes in the concentration of lipopolysaccharide after consumption of placebo or sucralose capsules for 30 days B) I percentage change for M/I value adjusted by fat free mass



**Presentation Preference (Complete):** Oral Preferred

**Financial Support (Complete):**

\* **ADA Support:** No

**Supported by:** : CONAHCYT Ciencia de Frontera 2019/316514

**Payment (Complete):** Your credit card order has been processed on Saturday 6 January 2024 at 7:42 PM.

**Status:** Complete

[American Diabetes Association](#)

2451 Crystal Drive, Suite 900

Arlington, VA 22202

For questions regarding the abstract submission process, email [abstracts@diabetes.org](mailto:abstracts@diabetes.org)

For Technical Support please contact [cOASIS Helpdesk](#) at [diabetes@support.ctimeetingtech.com](mailto:diabetes@support.ctimeetingtech.com) or 217-398-1792  
between the hours of 7:00 AM and 6:00 PM (CT) Monday through Friday.

💡 Feedback

---

Powered by [cOASIS](#), The Online Abstract Submission and Invitation System <sup>SM</sup>

© 1996 - 2024 [CTI Meeting Technology](#). All rights reserved. [Privacy Policy](#).